Treatment of Hidradenitis Suppurativa with Biologics

Speciality: Dermatology


Speaker:

Dr. Revathi D - Moderator | Dermatologist

Dr. Sudheshnadevi HP - Panelist | Dermatologist

Dr. Kumaralakshmanan S - Panelist | Dermatologist

Dr. Apoorva R - Panelist | Dermatologist

Dr. M Kumaresan - Panelist | Dermatologist

Description:

A warm welcome to all the medical professionals in this interesting session on treatment of hidradenitis suppurativa with biologics.

Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by painful, inflamed nodules and abscesses, often in areas like the armpits, groin, and under the breasts. For patients with moderate to severe cases, traditional treatments like antibiotics and steroids may not be enough. This is where biologic therapies have shown promise.

Biologics are advanced medications that target specific parts of the immune system, which play a key role in the inflammation seen in HS. One of the most commonly used biologics for HS is adalimumab, a TNF-alpha inhibitor. By blocking the inflammatory signals, it helps reduce the frequency and severity of flare-ups.

Clinical trials and real-world evidence have demonstrated the effectiveness of biologics in reducing both pain and the number of lesions in HS patients. These therapies also help prevent new lesions from forming, offering a lifeline for those who have not responded to conventional treatments.

However, biologic treatments are not without risks. They can lower the immune system's ability to fight infections, so patients must be closely monitored. Despite these risks, for many living with the debilitating symptoms of HS, biologics provide much-needed relief and significantly improve their quality of life.

Therefore, get an overall knowledge treatment of hidradenitis suppurativa with biologics. Listen to the webinar, grab the shared knowledge, and follow Hid

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot